Imunon (IMNN) 10-Q 11 May 18 2018 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2018	May 10, 2018
Document Information [Line Items]
Entity Registrant Name	Celsion Corp
Entity Central Index Key	749,647
Trading Symbol	clsn
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		17,740,035
Document Type	10-Q
Document Period End Date	Mar. 31, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q1
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 2,285,314	$ 11,444,055
Investment securities – available for sale, at fair value	18,411,162	12,724,020
Accrued interest receivable on investment securities	67,192	54,440
Advances, deposits and other current assets	89,186	89,186
Subtotal current assets	20,852,854	24,311,701
Property and equipment (at cost, less accumulated depreciation and amortization of $2,869,058 and $2,838,716 respectively)	(175,066)	(175,771)
Other assets:
In-process research and development	20,246,491	20,246,491
Other intangible assets, net	738,779	795,608
Goodwill	1,976,101	1,976,101
Patent licensing fees and other assets, net	8,761	8,761
Subtotal other assets	22,970,132	23,026,961
Total assets	43,998,052	47,514,433
Current liabilities:
Accounts payable - trade	3,416,878	3,416,863
Other accrued liabilities	1,716,867	2,282,827
Deferred revenue – current portion	500,000	500,000
Subtotal current liabilities	5,633,745	6,199,690
Earn-out milestone liability	12,808,720	12,538,525
Deferred revenue – non-current portion	1,875,000	2,000,000
Other liabilities – non-current portion	70,232	71,710
Total liabilities	20,387,697	20,809,925
Commitments and contingencies
Stockholders’ equity:
Preferred Stock - $0.01 par value (100,000 shares authorized and no shares issued or outstanding at March 31, 2018 and December 31, 2017)
Common stock - $0.01 par value (112,500,000 shares authorized; 17,740,369 and 17,277,299 shares issued at March 31, 2018 and December 31, 2017, respectively, and 17,740,035 and 17,276,965 shares outstanding at March 31, 2018 and December 31, 2017, respectively)	177,403	172,772
Additional paid-in capital	289,810,437	288,408,976
Accumulated other comprehensive loss	(33,414)	(10,164)
Accumulated deficit	(266,258,883)	(261,781,888)
Subtotal	23,695,543	26,789,696
Treasury stock, at cost (334 shares at March 31, 2018 and December 31, 2017)	(85,188)	(85,188)
Total stockholders’ equity	23,610,355	26,704,508
Total liabilities and stockholders’ equity	$ 43,998,052	$ 47,514,433

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, authorized (in shares)	100,000	100,000
Preferreed stock, issued (in shares)	0	0
Preferred stock, outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, authorized (in shares)	112,500,000	112,500,000
Common stock, issued (in shares)	17,740,369	17,277,299
Common stock, outstanding (in shares)	17,740,035	17,276,965
Property and equipment, accumulated depreciation	$ 2,869,058	$ 2,838,716
Treasury stock (in shares)	334	334

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Licensing revenue	$ 125,000	$ 125,000
Operating expenses:
Research and development	2,741,076	3,475,276
General and administrative	1,665,028	1,468,122
Total operating expenses	4,406,104	4,943,398
Loss from operations	(4,281,104)	(4,818,398)
Other (expense) income:
Loss from change in valuation of earn-out milestone liability	(270,195)	(283,751)
Investment income	73,724	1,991
Interest expense		(62,340)
Other income (expense)	580	2,362
Total other (expense) income, net	(195,891)	(341,738)
Net loss	$ (4,476,995)	$ (5,160,136)
Net loss per common share
Basic and diluted (in dollars per share)	$ (0.25)	$ (3.09)
Weighted average shares outstanding
Basic and diluted (in shares)	17,683,847	1,670,582

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Other comprehensive loss
Change in unrealized loss on available for sale securities	$ (23,250)
Net loss	(4,476,995)	(5,160,136)
Comprehensive loss	$ (4,500,245)	$ (5,160,136)

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Cash flows from operating activities:
Net loss	$ (4,476,995)	$ (5,160,136)
Non-cash items included in net loss:
Depreciation and amortization	87,171	170,529
Change in fair value of earn-out milestone liability	270,195	283,751
Deferred revenue	(125,000)	(125,000)
Stock-based compensation costs	153,668	117,466
Restricted shares issued	15,840
Amortization of deferred finance charges and debt discount associated with notes payable		17,685
Change in deferred rent liability	(1,478)	(9,264)
Net changes in:
Accrued interest on investment securities	(12,752)	4,008
Advances, deposits and other current assets		62,786
Accounts payable and accrued liabilities	(565,945)	1,508,171
Net cash (used in) operating activities:	(4,655,296)	(3,130,004)
Cash flows from investing activities:
Purchases of investment securities	(5,710,392)
Proceeds from sale and maturity of investment securities		1,680,000
Purchases of property and equipment	(29,637)	(21,126)
Net cash (used in) provided by investing activities	(5,740,029)	1,658,874
Cash flows from financing activities:
Proceeds from sale of common stock equity, net of issuance costs	1,236,584	4,284,373
Proceeds from exercise of common stock warrants		138,563
Principal payments on notes payable		(1,106,392)
Net cash provided by (used in) financing activities	1,236,584	3,316,544
(Decrease) increase in cash and cash equivalents	(9,158,741)	1,845,414
Cash and cash equivalents at beginning of period	11,444,055	2,624,162
Cash and cash equivalents at end of period	2,285,314	4,469,576
Supplemental disclosures of cash flow information:
Interest paid		$ 44,655

Note 1 - Business Description

Note 1 - Business Description	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Nature of Operations [Text Block]	Note 1. Business Description Celsion Corporation, a Delaware corporation based in Lawrenceville, New Jersey, and its wholly owned subsidiary, CLSN Laboratories, Inc., also a Delaware corporation, referred to herein as “Celsion”, “we”, or “the Company,” as the context requires, is a fully-integrated, development stage oncology drug company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. Our lead program is ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in Phase III development for the treatment of primary liver cancer. Our product pipeline also includes GEN- 1, three

Note 2 - Basis of Presentation

Note 2 - Basis of Presentation	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Basis of Accounting [Text Block]	Note 2. Basis of Presentation The accompanying unaudited condensed consolidated financial statements, which include the accounts of Celsion Corporation, CLSN Laboratories, Inc. and Celsion GmbH, have been prepared in accordance with generally accepted accounting principles in the United States (GAAP) for interim financial information and with the instructions to Form 10 10 X. In the opinion of management, all adjustments, consisting only of normal recurring accruals considered necessary for a fair presentation, have been included in the accompanying unaudited condensed consolidated financial statements. Operating results for the three March 31, 2018 not may 10 December 31, 2017 March 27, 2018. The preparation of financial statements in conformity with GAAP requires management to make judgments, estimates, and assumptions that affect the amount reported in the Company’s financial statements and accompanying notes. Actual results could differ materially from those estimates. Events and conditions arising subsequent to the most recent balance sheet date have been evaluated for their possible impact on the financial statements and accompanying notes. No

Note 3 - Financial Condition an

Note 3 - Financial Condition and Business Plan	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	Note 3. Financial Condition and Business Plan Since inception, the Company has incurred substantial operating losses, principally from expenses associated with the Company’s research and development programs, clinical trials conducted in connection with the Company’s product candidates, and applications and submissions to the Food and Drug Administration. We have not $266 March 31, 2018, $20.8 The Company expects its operating losses to continue for the foreseeable future as it continues its product development efforts, and when it undertakes marketing and sales activities. The Company’s ability to achieve profitability is dependent upon its ability to obtain governmental approvals, produce, and market and sell its new product candidates. There can be no The actual amount of funds the Company will need to operate is subject to many factors, some of which are beyond the Company’s control. These factors include the following: ● the progress of research activities; ● the number and scope of research programs; ● the progress of preclinical and clinical development activities; ● the progress of the development efforts of parties with whom the Company has entered into research and development agreements; ● the costs associated with additional clinical trials of product candidates; ● the ability to maintain current research and development licensing arrangements and to establish new research and development and licensing arrangements; ● the ability to achieve milestones under licensing arrangements; ● the costs involved in prosecuting and enforcing patent claims and other intellectual property rights; and ● the costs and timing of regulatory approvals. The Company has based its estimate on assumptions that may may may With the $20.8 March 31, 2018, third 2019. 11, $12.2 March 31, 2018 .

Note 4 - New Accounting Pronoun

Note 4 - New Accounting Pronouncements	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Description of New Accounting Pronouncements Not yet Adopted [Text Block]	Note 4. New Accounting Pronouncements From time to time, new accounting pronouncements are issued by Financial Accounting Standards Board (FASB) and are adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued accounting pronouncements will not not In May 2014, No. 2014 09 606 2014 09 January 1, 2017; 2015 14, 606 2014 09 one January 1, 2018. March 2016, No. 2016 8, 606 not No. 2014 09 No. 2014 09. April 2016, No. 2016 10, January 1, 2018. five No. 2014 09; 15, one five January 1, 2018 not In January 2016, No. 2016 01, December 15, 2017. 2016 01 not In February 2016, No. 2016 02, 842 twelve December 15, 2018, In August 2016, No. 2016 15, 230 December 15, 2017, 2016 01 not In November 2016, No. 2016 18, 230 230, December 15, 2017, 2016 01 not In January 2017, No. 2017 01, 805 December 15, 2018, In January 2017 , No. 2017 04, 2 not December 15, 2019, 2017.

Note 5 - Net Loss Per Common Sh

Note 5 - Net Loss Per Common Share	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Earnings Per Share [Text Block]	Note 5 . Net Loss per Common Share Basic loss per share is calculated based upon the net loss available to common shareholders divided by the weighted average number of common shares outstanding during the period. Diluted loss per share is calculated after adjusting the denominator of the basic earnings per share computation for the effects of all dilutive potential common shares outstanding during the period. The dilutive effects of preferred stock, options and warrants and their equivalents are computed using the treasury stock method. The total number of shares of common stock issuable respectively upon exercise of warrants, stock option grants and equity awards was 3,655,643 2,684,841 three March 31, 2018 2017 three March 31, 2018 2017,

Note 6 - Fair Value of Financia

Note 6 - Fair Value of Financial Instruments	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Derivatives and Fair Value [Text Block]	Note 6. Fair Value of Financial Instruments Short-term investments available for sale of $18,411,162 $12,724,020 March 31, 2018 December 31, 2017, Securities available for sale are evaluated periodically to determine whether a decline in their value is other than temporary. The term “other than temporary” is not not A summary of the cost, fair value and maturities of the Company’s short-term investments is as follows: March 31, 2018 December 31, 2017 Cost Fair Value Cost Fair Value Short-term investments Certificate of deposit $ 1,714,375 $ 1,713,833 $ - $ - Corporate debt securities 16,730,201 16,697,329 12,734,184 12,724,020 Total $ 18,444,576 $ 18,411,162 $ 12,734,184 12,724,020 March 31, 2018 December 31, 2017 Cost Fair Value Cost Fair Value Short-term investment maturities Within 3 months $ 4,996,672 $ 4,993,850 $ - $ - Between 3-12 months 13,447,904 13,417,312 12,734,184 12,724,020 Total $ 18,444,576 $ 18,411,162 $ 12,734,184 $ 12,724,020 Investment income, which includes net realized losses on sales of available for sale securities and investment income interest and dividends, is summarized as follows: Three Months Ended March 31, Description of Securities 2018 2017 Interest and dividends accrued and paid $ 69,289 $ 1,991 Realized gains 4,435 - Investment income $ 73,724 $ 1,991 The following table shows the Company’s investment securities gross unrealized losses and fair value by investment category and length of time that individual securities have been in a continuous unrealized loss position at March 31, 2018 December 31, 2017. March 31, 2018 December 31, 2017 Description of Securities Fair Value Unrealized Holding Gains (Losses) Fair Value Unrealized Holding Gains (Losses) Available for Sale (all unrealized holding gains and losses are less than 12 months at date of measurement) Investments with unrealized gains $ 2,239,849 $ 1,463 $ 748,148 $ 570 Investments with unrealized losses 16,171,313 (35,877 ) 11,975,872 (10,734 ) Total $ 18,411,162 $ (34,414 ) $ 12,724,020 $ (10,164 )

Note 7 - Fair Value of Measurem

Note 7 - Fair Value of Measurements	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Fair Value Disclosures [Text Block]	Note 7 . Fair Value Measurements FASB Accounting Standards Codification (ASC) Section 820 three three may Level 1: Level 2: 1 not Level 3: The fair values of securities available for sale are determined by obtaining quoted prices on nationally recognized exchanges (Level 1 2 Cash and cash equivalents, other current assets, accounts payable and other accrued liabilities are reflected in the balance sheet at their estimated fair values primarily due to their short-term nature. There were no 1 2 no 3 three March 31, 2018 2017. 3 13 Assets and liabilities measured at fair value are summarized below: Total Fair Value Quoted Prices In Active Markets For Identical Assets/Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: Recurring items as of March 31, 2018 Investment securities, available for sale $ 18,411,162 $ 18,411,162 ─ $ ─ Recurring items as of December 31, 2017 Investment securities, available for sale $ 12,724,020 $ 12,724,020 ─ $ ─ Liabilities: Recurring items as of March 31, 2018 Earn-out milestone liability (Note 13) $ 12,808,720 $ ─ ─ $ 12,808,720 Recurring items as of December 31, 2017 Earn-out milestone liability (Note 13) $ 12,538,525 $ ─ ─ $ 12,538,525

Note 8 - Acquisition of EGEN As

Note 8 - Acquisition of EGEN Assets	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Business Combination Disclosure [Text Block]	Note 8 . Acquisition of EGEN Assets On June 20, 2014, June 6, 2014, The total purchase price for the asset acquisition is up to $44.4 $30.4 $3.0 193,728 4 2 47,862 June 16, 2017. After its review in 2016, no 2017 $24.4 may two ● $12.4 1 001 ● $12.0 1 The following table summarizes the fair values of these assets acquired and liabilities assumed related to the acquisition. Property and equipment, net $ 35,000 In-process research and development 24,211,000 Other Intangible assets (Covenant not to compete) 1,591,000 Goodwill 1,976,000 Total assets: 27,813,000 Accounts payable and accrued liabilities (235,000 ) Net assets acquired $ 27,578,000 Acquired in-process research and development (IPR&D) consists of EGEN's drug technology platforms: TheraPlas and TheraSilence. The fair value of the IPR&D drug technology platforms was estimated to be $24.2 not third September 30, not At September 30, 2017, may September 30, 2017 $9.4 $6.9 $2.5 third 2017. At December 31, 2016, one may $1.4 $1.4 fourth 2016. As no first 2018, none March 31, 2018. Pursuant to the EGEN Purchase Agreement, EGEN provided certain covenants (“Covenant Not seventh June 20, 2014, not Not $1.6 7 $ 56,829 three March 31, 2018 2017. Not $738,779 $852,435 March 31, 2018 $795,608 $795,606 December 31, 2017 The purchase price exceeded the estimated fair value of the net assets acquired by approximately $2.0 third September 30 September 30, 2017, not not”

Note 9 - Accrued Liabilities

Note 9 - Accrued Liabilities	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	Note 9 . Accrued Liabilities Other accrued liabilities at March 31, 2018 December 31, 2017 Year Ended December 31, 201 8 201 7 Amounts due to contract research organizations and other contractual agreements $ 837,955 $ 665,373 Accrued payroll and related benefits 550,143 1,258,265 Accrued professional fees 308,748 264,668 Other 20,021 94,521 Total $ 1,716,867 $ 2,282,827

Note 10 - Note Payable

Note 10 - Note Payable	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Debt Disclosure [Text Block]	Note 10 . Note Payable In November 2013, $20 first $5 November 2013 $4 June 10, 2014, second $5 $3.0 second $10 The obligations under the Hercules Credit Agreement are in the form of secured indebtedness bearing interest at a calculated prime-based variable rate ( 11.25% December 17, 2015, 11.50% December 18, 2015 December 15, 2016 11.75% first twelve 30 June 1, 2017. $122,378 $230,000 As a fee associated with the Hercules Credit Agreement, the Company issued Hercules a warrant for a total of 6,963 $50.26, November 25, 2013. second June 10, 2014, 6,963 November 25, 2018. November 25, 2013. may 144 first 415 1933 No. 333 193936 September 30, 2014. $476,261 $5.0 3.5% $350,000 three March 31, 2017 $44,655 $17,685 The loan balance and end of term charges on the Hercules Credit Agreement was paid in full in June 2017.

Note 11 - Stockholders' Equity

Note 11 - Stockholders' Equity	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	Note 1 1 . Stockholders’ Equity In September 2015, $75 3 2015 No. 333 206789 September 25, 2015. At the 2016 June 2016, 75,000,000 112,500,000 100,000 may 112,600,000 Reverse Stock Split On May 26, 2017, 14 1 May 30, 2017. 14 one 14 1 May 30, 2017, 15117N503 The reverse stock split was previously approved by the Company’s stockholders at the 2017 May 16, 2017, ● To increase the market price of the Company’s common stock making it more attractive to a broader range of institutional and other investors, and ● To provide the Company with additional capital resources and flexibility sufficient to execute its business plans including the establishment of strategic relationships with other companies and to ensure its ability to raise additional capital as necessary. Immediately prior to the reverse stock split, the Company had 56,982,418 4,070,172 No 2.4 0.2 33.5 2.4 October 2017 Underwritten Offering On October 27, 2017, 2,640,000 $0.01 1,320,000 0.5 one $2.50 Pursuant to the terms of the Underwriting Agreement, the Underwriter agreed to purchase the Shares and related Investor Warrants from the Company at a price of $2.325 six $3.00 five first The Company received $6.6 3 No. 333 206789 September 4, 2015, September 25, 2015, September 25, 2017 66,000 4 2 six $2.87 five first . July 6, 2017 Common Stock Offering On July 6, 2017, 2,050,000 $2.07 $4,243,500 385,000 9.99% $2.06 $793,100, $0.01 not one six five one $2.07 2,435,000 twelve $4.75 2,435,000 not 9.99% fourth 2017, 385,000 On October 4, 2017, July 6, 2017 not January 11, 2018. 4,665,000 $2.07 $4.75 $16.6 The Exercise Agreements also provide for the issuance of 1,166,250 one $6.20, one six 4 2 506 February 14, 2017 Public Offering On February 14, 2017, February 14, 2017 1,384,704 $3.22 1,177,790 185,713 $3.22 five $3.08 $0.14 not 9.99% $5.0 February 14, 2017 In connection with the February 14, 2017 1 No. 333 215321 December 23, 2016, No. 1 January 20, 2017, No. 2 February 13, 2017, No. 3 February 13, 2017 No. 4 February 14, 2017 1933, As of December 31, 2017, 185,713 2017, $2.4 747,254 Reduced Exercise Price of Warrants On February 22, 2013, “2013 95,811 $74.34 January 15, 2014, “2014 64,348 $57.40 June 9, 2017, 2013 2014 June 2016 790,410 2013 2014 June 2016 790,410 $2.70 $2.1 2013 2014 June 2016 The reduced exercise price of the 2013 2014 June 2016 $0.2 On May 27, 2015 “2015 139,284 $36.40 June 22, 2017 June 26, 2017, 2015 December 2016 2015 June 2016 506,627 $1.65 $0.8 2015 June 2016 The reduced exercise price of the 2015 $0.1 Common Stock Warrants As of March 31, 2018, December 31, 2017, 3,058,402 $5.29. 3.3 March 31, 2018. Controlled Equity Offering On February 1, 2013, may $25.0 3. may 415 1933, February 1, 2013 March 31, 2018, 1,784,396 $12.8 The Company is not may may The ATM Agreement will terminate upon the earlier of (i) the sale of ATM Shares under the ATM Agreement having an aggregate offering price of $25 may 10 3.0% $50,000 On October 2, 2015 February 6, 2018, 2015 may $17.5 January 2018 2018, 457,070 $1.3 $12.2

Note 12 - Stock-based Compensat

Note 12 - Stock-based Compensation	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	Note 12 . Stock-Based Compensation The Company has long-term compensation plans that permit the granting of equity based-awards in the form of stock options, restricted stock, restricted stock units, stock appreciation rights, phantom stock, and performance awards. Generally, the terms of these plans require that the exercise price of the options may not ten The Celsion Corporation 2007 2007 688,531 2007 two one 2001 2004 21,164 2007 2007 The Company has issued stock awards to employees, directors and vendors out of the stock option plans. Options are generally granted with strike prices equal to the market value on the date of the grant. Incentive stock options may not 100% 10% 110% may may Option awards vest upon terms determined by the Board of Directors. Restricted stock awards, performance stock awards and stock options are subject to accelerated vesting in the event of a change of control. The Company issues new shares to satisfy its obligations from the exercise of options. As of March 31, 2018, 705,893 597,241 102,652 Total compensation cost charged related to employee stock options and restricted stock awards amounted to $169,508 $117,466 three March 31, 2018 2017, March 31, 2018, $0.4 0.9 three March 31, 2018 $2.27. No three March 31, 2017. A summary of stock option awards and restricted stock grants for the three March 31, 2018 Stock Options Restricted Stock Awards Weighted Average Equity Awards Options Outstanding Weighted Average Exercise Price Non-vested Restricted Stock Outstanding Weighted Average Grant Date Fair Value Contractual Terms of Equity Awards (in years) Equity awards outstanding at January 1, 2018 703,442 $ 10.34 – $ – Equity awards granted 7,500 $ 2.52 6,000 $ 2.64 Vested and issued – $ – (6,000 ) $ 2.64 Equity awards forfeited, cancelled or expired (113,701 ) $ 40.23 – $ – Equity awards outstanding at March 31, 2018 597,241 $ 4.48 – $ – 9.1 Aggregate intrinsic value of outstanding awards at March 31, 2018 $ 2,750 $ – Equity awards exercisable at March 31, 2018 320,877 $ 5.79 9.0 Aggregate intrinsic value of awards exercisable at March 31, 2018 $ – The fair values of stock options granted were estimated at the date of grant using the Black-Scholes option pricing model. The Black-Scholes model was originally developed for use in estimating the fair value of traded options, which have different characteristics from Celsion’s stock options. The model is also sensitive to changes in assumptions, which can materially affect the fair value estimate. The Company used the following assumptions for determining the fair value of options granted under the Black-Scholes option pricing model: Three months ended March 31, 2018 Risk-free interest rate 2.82 % Expected volatility 99.9 % Expected life (in years) 10 Expected dividend yield 0.0 % Expected volatilities utilized in the model are based on historical volatility of the Company’s stock price. The risk-free interest rate is derived from values assigned to U.S. Treasury bonds with terms that approximate the expected option lives in effect at the time of grant. Starting in 2017, 2018

Note 13 - Earn-out Milestone Li

Note 13 - Earn-out Milestone Liability	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Earn-out Milestone Liability Disclosure [Text Block]	Note 1 3 . Earn-out Milestone Liability The total aggregate purchase price for the EGEN Acquisition included potential future Earn-out Payments contingent upon achievement of certain milestones. The difference between the aggregate $30.4 $13.9 June 20, 2014 10% 67% 1.5 2.5 As of March 31, 2018, December 31, 2017, $12.8 $12.5 $270,195 three March 31, 2018 December 31, 2015. March 31, 2017, December 31, 2016, $13.5 $13.2 $283,751 three March 31, 2017 December 31, 2016. The following is a summary of the changes in the earn-out milestone liability for 2018: Balance at January 1, 2018 $ 12,538,525 Non-cash charge from the adjustment for the change in fair value included in net loss 270,195 Balance at March 31, 2018 $ 12,808,720 The following is a schedule of the Company’s risk-adjustment assessment of each milestone: Date Risk-adjustment Assessment of each Milestone Discount Rate Estimated Time to Achieve (in years) March 31, 2018 35% to 80% 9% 1.08 to 1.25 December 31, 2017 35% to 80% 9% 1.33 to 1.50 March 31, 2017 50% to 80% 9% 1.75 to 2.25 December 31, 2016 50% to 80% 9% 2.00 to 2.50

Note 14 - Contingent Liabilitie

Note 14 - Contingent Liabilities and Commitments	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	Note 1 4 . Contingent Liabilities and Commitments In July 2011, 10,870 October 2011, 66 6 first $23,000 April 2012. $250,000, $50,000 19th, 31st 43rd $100,000 April 2017. 2015, April 30, 2017. April 2017, May 1, 2017. 64 7,565 four $18,900 first $20,500 one 24th In connection with the EGEN Asset Purchase Agreement in June 2014, 11,500 January 2018. January 2018, 60 9,049 $18,100

Note 15 - Technology Developmen

Note 15 - Technology Development and Licensing Agreements	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Licensing Transaction [Text Block]	No te 15 . Technology Development and Licensing Agreements On May 7, 2012, three first 2015, three On January 18, 2013, $5 ® January 31, 2013 January 18, 2013 ® ® $5.0 first 2013 10 ® On July 19, 2013, Among the key provisions of the Celsion-Hisun Memorandum of Understanding are: ● Hisun will provide the Company with non-dilutive financing and the investment necessary to complete the technology transfer of its proprietary manufacturing process and the production of registration batches for the China territory; ● Hisun will collaborate with the Company around the clinical and regulatory approval activities for ThermoDox® as well as other liposomal formations with the CHINA FDA; and ● Hisun will be granted a right of first On August 8, 2016, 1 1, 12 1 1 1 first Key provisions of the GEN- 1 ● the GEN- 1 1 ● once approved, the cost structure for GEN- 1 ● Celsion will provide Hisun a certain percentage of China’s commercial unit demand, and separately of global commercial unit demand, subject to regulatory approval; ● Hisun and Celsion will commence technology transfer activities relating to the manufacture of GEN- 1, ● Hisun will collaborate with Celsion around the regulatory approval activities for GEN- 1

Note 6 - Fair Value of Financ22

Note 6 - Fair Value of Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2018
Notes Tables
Schedule of Cost, Fair Value and Maturities of Short-term Investments [Table Text Block]	March 31, 2018 December 31, 2017 Cost Fair Value Cost Fair Value Short-term investments Certificate of deposit $ 1,714,375 $ 1,713,833 $ - $ - Corporate debt securities 16,730,201 16,697,329 12,734,184 12,724,020 Total $ 18,444,576 $ 18,411,162 $ 12,734,184 12,724,020 March 31, 2018 December 31, 2017 Cost Fair Value Cost Fair Value Short-term investment maturities Within 3 months $ 4,996,672 $ 4,993,850 $ - $ - Between 3-12 months 13,447,904 13,417,312 12,734,184 12,724,020 Total $ 18,444,576 $ 18,411,162 $ 12,734,184 $ 12,724,020
Investment Income [Table Text Block]	Three Months Ended March 31, Description of Securities 2018 2017 Interest and dividends accrued and paid $ 69,289 $ 1,991 Realized gains 4,435 - Investment income $ 73,724 $ 1,991
Schedule of Unrealized Loss on Investments [Table Text Block]	March 31, 2018 December 31, 2017 Description of Securities Fair Value Unrealized Holding Gains (Losses) Fair Value Unrealized Holding Gains (Losses) Available for Sale (all unrealized holding gains and losses are less than 12 months at date of measurement) Investments with unrealized gains $ 2,239,849 $ 1,463 $ 748,148 $ 570 Investments with unrealized losses 16,171,313 (35,877 ) 11,975,872 (10,734 ) Total $ 18,411,162 $ (34,414 ) $ 12,724,020 $ (10,164 )

Note 7 - Fair Value of Measur23

Note 7 - Fair Value of Measurements (Tables)	3 Months Ended
	Mar. 31, 2018
Notes Tables
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	Total Fair Value Quoted Prices In Active Markets For Identical Assets/Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: Recurring items as of March 31, 2018 Investment securities, available for sale $ 18,411,162 $ 18,411,162 ─ $ ─ Recurring items as of December 31, 2017 Investment securities, available for sale $ 12,724,020 $ 12,724,020 ─ $ ─ Liabilities: Recurring items as of March 31, 2018 Earn-out milestone liability (Note 13) $ 12,808,720 $ ─ ─ $ 12,808,720 Recurring items as of December 31, 2017 Earn-out milestone liability (Note 13) $ 12,538,525 $ ─ ─ $ 12,538,525

Note 8 - Acquisition of EGEN 24

Note 8 - Acquisition of EGEN Assets (Tables)	3 Months Ended
	Mar. 31, 2018
Notes Tables
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	Property and equipment, net $ 35,000 In-process research and development 24,211,000 Other Intangible assets (Covenant not to compete) 1,591,000 Goodwill 1,976,000 Total assets: 27,813,000 Accounts payable and accrued liabilities (235,000 ) Net assets acquired $ 27,578,000

Note 9 - Accrued Liabilities (T

Note 9 - Accrued Liabilities (Tables)	3 Months Ended
	Mar. 31, 2018
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	Year Ended December 31, 201 8 201 7 Amounts due to contract research organizations and other contractual agreements $ 837,955 $ 665,373 Accrued payroll and related benefits 550,143 1,258,265 Accrued professional fees 308,748 264,668 Other 20,021 94,521 Total $ 1,716,867 $ 2,282,827

Note 12 - Stock-based Compens26

Note 12 - Stock-based Compensation (Tables)	3 Months Ended
	Mar. 31, 2018
Notes Tables
Schedule of Share-based Compensation Stock Options and Restricted Stock Awards Activity [Table Text Block]	Stock Options Restricted Stock Awards Weighted Average Equity Awards Options Outstanding Weighted Average Exercise Price Non-vested Restricted Stock Outstanding Weighted Average Grant Date Fair Value Contractual Terms of Equity Awards (in years) Equity awards outstanding at January 1, 2018 703,442 $ 10.34 – $ – Equity awards granted 7,500 $ 2.52 6,000 $ 2.64 Vested and issued – $ – (6,000 ) $ 2.64 Equity awards forfeited, cancelled or expired (113,701 ) $ 40.23 – $ – Equity awards outstanding at March 31, 2018 597,241 $ 4.48 – $ – 9.1 Aggregate intrinsic value of outstanding awards at March 31, 2018 $ 2,750 $ – Equity awards exercisable at March 31, 2018 320,877 $ 5.79 9.0 Aggregate intrinsic value of awards exercisable at March 31, 2018 $ –
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Three months ended March 31, 2018 Risk-free interest rate 2.82 % Expected volatility 99.9 % Expected life (in years) 10 Expected dividend yield 0.0 %

Note 13 - Earn-out Milestone 27

Note 13 - Earn-out Milestone Liability (Tables)	3 Months Ended
	Mar. 31, 2018
Notes Tables
Schedule of Changes in Earn out Milestone Liabilities [Table Text Block]	Balance at January 1, 2018 $ 12,538,525 Non-cash charge from the adjustment for the change in fair value included in net loss 270,195 Balance at March 31, 2018 $ 12,808,720
Schedule of Milestone Risk Adjustment Assessment [Table Text Block]	Date Risk-adjustment Assessment of each Milestone Discount Rate Estimated Time to Achieve (in years) March 31, 2018 35% to 80% 9% 1.08 to 1.25 December 31, 2017 35% to 80% 9% 1.33 to 1.50 March 31, 2017 50% to 80% 9% 1.75 to 2.25 December 31, 2016 50% to 80% 9% 2.00 to 2.50

Note 3 - Financial Condition 28

Note 3 - Financial Condition and Business Plan (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Retained Earnings (Accumulated Deficit), Ending Balance	$ (266,258,883)	$ (261,781,888)
Cash, Investment Securities and Interest Receivable	20,800,000
Aggregate Offering Price, Additions	$ 12,200,000

Note 5 - Net Loss Per Common 29

Note 5 - Net Loss Per Common Share (Details Textual) - shares	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Number of Shares of Common Stock Issuable Upon Exercise of Warrants and Equity Awards	3,655,643	2,684,841

Note 6 - Fair Value of Financ30

Note 6 - Fair Value of Financial Instruments (Details Textual) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Debt Securities, Available-for-sale, Current, Total	$ 18,411,162	$ 12,724,020

Note 6 - Fair Value of Financ31

Note 6 - Fair Value of Financial Instruments- Summary of Cost, Fair Value and Maturities of Short-term Investments (Details) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Cost	$ 18,444,576	$ 12,734,184
Investment securities – available for sale, at fair value	18,411,162	12,724,020
Within 3 months, cost	4,996,672
Within 3 months, fair value	4,993,850
Between 3-12 months, cost	13,447,904	12,734,184
Between 3-12 months, fair value	13,417,312	12,724,020
Total, cost	18,444,576	12,734,184
Total, fair value	18,411,162	12,724,020
Certificates of Deposit [Member]
Cost	1,714,375
Investment securities – available for sale, at fair value	1,713,833
Total, cost	1,714,375
Corporate Debt Securities [Member]
Cost	16,730,201	12,734,184
Investment securities – available for sale, at fair value	16,697,329	12,724,020
Total, cost	$ 16,730,201	$ 12,734,184

Note 6 - Fair Value of Financ32

Note 6 - Fair Value of Financial Instruments - Summary of Investment Income (Details) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Interest and dividends accrued and paid	$ 69,289	$ 1,991
Realized gains	4,435
Investment income	$ 73,724	$ 1,991

Note 6 - Fair Value of Financ33

Note 6 - Fair Value of Financial Instruments - Unrealized Losses (Details) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Less than 12 months, unrealized gains, fair value	$ 2,239,849	$ 748,148
Less than 12 months, unrealized gains	1,463	570
Less than 12 months, unrealized losses, fair value	16,171,313	11,975,872
Less than 12 months, unrealized losses	(35,877)	(10,734)
Investment securities – available for sale, at fair value	18,411,162	12,724,020
Unrealized gains (losses)	$ (34,414)	$ (10,164)

Note 7 - Fair Value of Measur34

Note 7 - Fair Value of Measurements (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Fair Value, Assets, Level 1 to Level 2 Transfers, Amount	$ 0	$ 0
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Transfers into Level 3	$ 0	$ 0

Note 7 - Fair Value of Measur35

Note 7 - Fair Value of Measurements - Assets and Liabilities at Fair Value on a Recurring Basis (Details) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Investment securities, available for sale	$ 18,411,162	$ 12,724,020
Earn-out milestone liability (Note 13)	12,808,720	12,538,525
Fair Value, Measurements, Recurring [Member]
Investment securities, available for sale	18,411,162	12,724,020
Earn-out milestone liability (Note 13)	12,808,720	12,538,525
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Investment securities, available for sale	18,411,162	12,724,020
Earn-out milestone liability (Note 13)
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Investment securities, available for sale
Earn-out milestone liability (Note 13)	$ 12,808,720	$ 12,538,525

Note 8 - Acquisition of EGEN 36

Note 8 - Acquisition of EGEN Assets (Details Textual) - USD ($)	Jun. 16, 2017	Jun. 20, 2014	Mar. 31, 2018	Sep. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2017	Dec. 31, 2017
Finite-Lived Intangible Asset, Useful Life						7 years
Finite-Lived Intangible Assets, Net, Ending Balance			$ 738,779					$ 795,608
Noncompete Agreements [Member]
Amortization of Intangible Assets, Total			56,829		$ 56,829
Finite-Lived Intangible Assets, Net, Ending Balance			738,779					795,608
Finite-Lived Intangible Assets, Accumulated Amortization			$ 852,435					795,606
Indefinite-lived in Process Research and Development [Member]
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)						$ 1,400,000
EGEN Inc [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High		$ 30,400,000						24,400,000
Payments to Acquire Businesses, Gross		$ 3,000,000
Stock Issued During Period, Shares, Acquisitions		193,728
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	47,862
Goodwill, Acquired During Period		$ 2,000,000
EGEN Inc [Member] | Noncompete Agreements [Member]
Finite-Lived Intangible Asset, Useful Life						7 years
Finite-lived Intangible Assets Acquired						$ 1,600,000
EGEN Inc [Member] | Indefinite-lived in Process Research and Development [Member]
Indefinite-lived Intangible Assets Acquired		24,200,000		$ 6,900,000			$ 9,400,000
Asset Impairment Charges, Total				$ 2,500,000
EGEN Inc [Member] | Ovarian Cancer Study Milestone [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High								12,400,000
EGEN Inc [Member] | Glioblastoma Multiforme Brain Cancer Study Milestone [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High								$ 12,000,000
EGEN Inc [Member] | Maximum [Member]
Business Combination, Consideration Transferred, Total		$ 44,400,000

Note 8 - Acquisition of EGEN 37

Note 8 - Acquisition of EGEN Assets - Fair Values of Acquired Assets and Liabilities (Details) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Goodwill	$ 1,976,101	$ 1,976,101
EGEN Inc [Member]
Property and equipment, net	35,000
In-process research and development	24,211,000
Other Intangible assets (Covenant not to compete)	1,591,000
Goodwill	1,976,000
Total assets:	27,813,000
Accounts payable and accrued liabilities	(235,000)
Net assets acquired	$ 27,578,000

Note 9 - Accrued Liabilities -

Note 9 - Accrued Liabilities - Other Accrued Liabilities (Details) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Amounts due to contract research organizations and other contractual agreements	$ 837,955	$ 665,373
Accrued payroll and related benefits	550,143	1,258,265
Accrued professional fees	308,748	264,668
Other	20,021	94,521
Total	$ 1,716,867	$ 2,282,827

Note 10 - Note Payable (Details

Note 10 - Note Payable (Details Textual) - USD ($)

Jun. 10, 2014

Jun. 20, 2014

Nov. 30, 2013

Mar. 31, 2017

Jun. 10, 2014

Dec. 15, 2016

Mar. 31, 2018

Dec. 17, 2015

Mar. 31, 2018

Dec. 31, 2017

Jun. 26, 2017

Jun. 09, 2017

Jun. 30, 2015

Nov. 25, 2013

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 5.29

$ 5.29

$ 5.29

$ 1.65

$ 2.70

Hercules Warrant [Member]

Debt Instrument, Unamortized Discount, Total

$ 476,261

$ 476,261

EGEN Inc [Member]

Payments to Acquire Businesses, Gross

$ 3,000,000

Hercules Credit Agreement [Member]

Repayments of Lines of Credit

$ 4,000,000

Interest Expense, Debt, Total

$ 44,655

Amortization of Debt Issuance Costs

$ 17,685

Hercules Credit Agreement [Member] | Hercules Warrant [Member]

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 50.26

Line of Credit Facility Original Loan Fee Percent

3.50%

Debt Issuance Costs, Gross

$ 350,000

Hercules Credit Agreement [Member] | EGEN Inc [Member]

Payments to Acquire Businesses, Gross

3,000,000

Hercules [Member]

Repayments of Lines of Credit

$ 5,000,000

Hercules [Member] | Hercules Credit Agreement [Member]

Line of Credit Facility, Maximum Borrowing Capacity

20,000,000

Proceeds from Lines of Credit, Total

5,000,000

$ 10,000,000

Debt Instrument, Basis Spread on Variable Rate

11.50%

11.75%

11.25%

Amortization Period for Principal and Interest

2 years 180 days

Debt Issuance Costs, Net, Total

122,378

Debt Instrument, Unamortized Discount, Total

$ 230,000

Hercules [Member] | Hercules Credit Agreement [Member] | First Fifty Percent [Member]

Class of Warrant or Right, Number of Securities Called by Each Warrant or Right

6,963

6,963

Hercules [Member] | Hercules Credit Agreement [Member] | Second Fifty Percent [Member]

Class of Warrant or Right, Number of Securities Called by Each Warrant or Right

6,963

Note 11 - Stockholders' Equity

Note 11 - Stockholders' Equity (Details Textual)	Oct. 31, 2017USD ($)	Oct. 27, 2017$ / sharesshares	Oct. 04, 2017USD ($)$ / sharesshares	Jul. 06, 2017USD ($)$ / sharesshares	Jun. 26, 2017USD ($)$ / sharesshares	Jun. 09, 2017USD ($)$ / sharesshares	May 26, 2017shares	Feb. 14, 2017USD ($)$ / sharesshares	Oct. 02, 2015USD ($)	Feb. 01, 2013USD ($)	Sep. 30, 2015USD ($)	Feb. 25, 2013USD ($)	Mar. 31, 2018USD ($)$ / sharesshares	Dec. 31, 2017$ / sharesshares	Mar. 31, 2017USD ($)	Dec. 31, 2017USD ($)$ / sharesshares	Mar. 31, 2018USD ($)$ / sharesshares	Sep. 30, 2017USD ($)	Dec. 31, 2017USD ($)$ / sharesshares	Mar. 31, 2018USD ($)$ / sharesshares	May 25, 2017shares	May 16, 2017shares	May 15, 2017shares	Jun. 30, 2016shares	May 31, 2016shares	May 27, 2015$ / sharesshares	Jan. 15, 2014$ / sharesshares	Feb. 22, 2013$ / sharesshares
Shelf Registration Statement Amount | $											$ 75,000,000
Common Stock, Shares Authorized													112,500,000	112,500,000		112,500,000	112,500,000		112,500,000	112,500,000				112,500,000	75,000,000
Preferred Stock, Shares Authorized													100,000	100,000		100,000	100,000		100,000	100,000				100,000
Aggregate of Common and Preferred Stock, Shares Authorized																								112,600,000
Common Stock, Shares, Outstanding, Ending Balance							4,070,172						17,740,035	17,276,965		17,276,965	17,740,035		17,276,965	17,740,035	56,982,418
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance													597,241	703,442		703,442	597,241		703,442	597,241		200,000	2,400,000
Class of Warrant or Right, Outstanding													3,058,402	3,058,402		3,058,402	3,058,402		3,058,402	3,058,402		2,400,000	33,500,000
Common Stock, Par or Stated Value Per Share | $ / shares													$ 0.01	$ 0.01		$ 0.01	$ 0.01		$ 0.01	$ 0.01
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					506,627	790,410
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares					$ 1.65	$ 2.70							$ 5.29	$ 5.29		$ 5.29	$ 5.29		$ 5.29	$ 5.29
Proceeds from Issuance of Common Stock | $													$ 1,300,000
Proceeds from Warrant Exercises | $															$ 138,563			$ 800,000	$ 2,100,000
Class of Warrant or Right, Weighted Average Remaining Contractual Term													3 years 109 days			3 years 109 days
Aggregate Offering Price, Additions | $													$ 12,200,000
Aggregate Offering Price, Remaining Amount | $																	$ 12,200,000
2013 Warrants, 2014 Warrants, and June 2016 Warrants [Member]
Increase (Decrease) in Fair Value of Warrants | $						$ 200,000
2015 Warrants [Member]
Increase (Decrease) in Fair Value of Warrants | $					$ 100,000
October 2017 Underwritten Offering [Member]
Stock Issued During Period, Shares, New Issues		2,640,000
Common Stock, Par or Stated Value Per Share | $ / shares		$ 0.01
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		1,320,000
Class of Warrant or Right, Number of Warrants Issued with Stock		0.5
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right		1
Class of Warrant or Right, Offered Price of Warrants or Rights | $ / shares		$ 2.50
Shares Issued, Price Per Share | $ / shares		$ 2.325
Class of Warrant or Right, Exercisable Period		180 days
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares		$ 3
Warrants Issued, Expiration Period		5 years
Proceeds from Issuance of Common Stock and Warrants | $	$ 6,600,000
October 2017 Underwritten Offering [Member] | Additional Warrants Issued to Underwriter [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		66,000
Class of Warrant or Right, Exercisable Period		180 days
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares		$ 2.87
Warrants Issued, Expiration Period		5 years
July 2017 Direct Offering [Member]
Stock Issued During Period, Shares, New Issues				2,050,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right			4,665,000
Share Price | $ / shares				$ 2.07
Proceeds from Issuance of Common Stock, Gross | $				$ 4,243,500
Proceeds from Issuance of Warrants | $			$ 16.60
July 2017 Direct Offering [Member] | Pre-Funded Series CCC Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				385,000
Class of Warrant or Right, Offered Price of Warrants or Rights | $ / shares				$ 2.06
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares				$ 0.01
Beneficial Ownership Percentage Threshold				9.99%
Proceeds from Issuance of Warrants | $				$ 793,100
Class of Warrant or Right, Exercised During Period														385,000
July 2017 Direct Offering [Member] | Series AAA Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				2,435,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right				1
Class of Warrant or Right, Exercisable Period				180 days
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares				$ 2.07
Warrants Issued, Expiration Period				5 years 182 days
July 2017 Direct Offering [Member] | Series BBB Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				2,435,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares				$ 4.75
Warrants Issued, Expiration Period				1 year
July 2017 Direct Offering [Member] | Series DDD Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			1,166,250
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right			1
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares			$ 6.20
February 14, 2017 Public Offering [Member]
Stock Issued During Period, Shares, New Issues								1,384,704
Shares Issued, Price Per Share | $ / shares								$ 3.22
Maximum Beneficial Ownership of the Purchaser								9.99%
Proceeds from Issuance of Common Stock | $								$ 5,000,000
February 14, 2017 Public Offering [Member] | Series AA Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights								1,177,790
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares								$ 3.22
Class of Warrant or Right, Term								5 years
Stock Issued During Period, Shares, Exercise of Warrants																747,254
Proceeds from Warrant Exercises | $																$ 2,400,000
February 14, 2017 Public Offering [Member] | Pre-Funded Series BB Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights								185,713
Shares Issued, Price Per Share | $ / shares								$ 3.08
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares								$ 0.14
Stock Issued During Period, Shares, Exercise of Warrants																185,713
February 2013 Preferred Stock Offering [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																												95,811
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares																												$ 74.34
January 2014 Common Stock Offering [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																											64,348
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares																											$ 57.40
May 2015 Common Stock Offering [Member] | 2015 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																										139,284
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares																										$ 36.40
ATM Agreement [Member]
Stock Issued During Period, Shares, New Issues													457,070							1,784,396
Proceeds from Issuance of Common Stock | $																				$ 12,800,000
Aggregate Offering Price | $										$ 25,000,000
Commission on Proceeds from ATM Shares Percent												3.00%
Legal Fees | $												$ 50,000
Aggregate Offering Price, Additions | $									$ 17,500,000
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio							14

Note 12 - Stock-based Compens41

Note 12 - Stock-based Compensation (Details Textual) - USD ($)	3 Months Ended		135 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2018	Dec. 31, 2017	May 16, 2017	May 15, 2017	Dec. 31, 2006
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized							21,164
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance	597,241		597,241	703,442	200,000	2,400,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 2.27
Stock Incentive Plan 2007 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	688,531		688,531
Percentage of Fair Market Value of Shares	100.00%		100.00%
Percentage of Outstanding Stock Determining Factor for Incentive Stock Price	10.00%		10.00%
Allocated Share-based Compensation Expense, Total	$ 169,508	$ 117,466
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total	$ 400,000		$ 400,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	328 days
Stock Incentive Plan 2007 [Member] | Minimum [Member]
Percentage of Fair Market Value of Shares	110.00%		110.00%
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period			10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance	705,893		705,893
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period	597,241
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	102,652		102,652

Note 12 - Stock-based Compens42

Note 12 - Stock-based Compensation - Stock Option and Restricted Stock (Details)	3 Months Ended
	Mar. 31, 2018USD ($)$ / sharesshares
Equity awards outstanding, options (in shares) | shares	703,442
Equity awards outstanding, weighted average exercise price (in dollars per share) | $ / shares	$ 10.34
Equity awards granted, options (in shares) | shares	7,500
Equity awards granted, weighted average exercise price (in dollars per share) | $ / shares	$ 2.52
Equity awards, vested and issued restricted stock (in shares) | shares	(6,000)
Vested and issued (in dollars per share) | $ / shares	$ 2.64
Equity awards forfeited, cancelled or expired, options (in shares) | shares	(113,701)
Equity awards forfeited, cancelled or expired, weighted average exercise price (in dollars per share) | $ / shares	$ 40.23
Equity awards outstanding, options (in shares) | shares	597,241
Equity awards outstanding, weighted average exercise price (in dollars per share) | $ / shares	$ 4.48
Equity awards outstanding, contractual term (Year)	9 years 36 days
Equity awards outstanding, intrinsic value | $	$ 2,750
Equity awards exercisable, options (in shares) | shares	320,877
Equity awards exercisable, weighted average exercise price (in dollars per share) | $ / shares	$ 5.79
Equity awards exercisable, contractual term (Year)	9 years
Aggregate intrinsic value of awards exercisable, options | $
Restricted Stock [Member]
Equity awards outstanding, non-vested restricted stock (in shares) | shares
Equity awards outstanding, non-vested restricted stock weighted average grant date fair value (in dollars per share) | $ / shares
Equity awards granted, non-vested restricted stock (in shares) | shares	6,000
Equity awards granted, non-vested restricted stock weighted average grant date fair value (in dollars per share) | $ / shares	$ 2.64
Equity awards forfeited, cancelled or expired, non-vested restricted stock (in shares) | shares
Equity awards forfeited, cancelled or expired, non-vested restricted stock weighted average grant date fair value (in dollars per share) | $ / shares
Equity awards outstanding, non-vested restricted stock (in shares) | shares
Equity awards outstanding, non-vested restricted stock weighted average grant date fair value (in dollars per share) | $ / shares
Aggregate intrinsic value of outstanding awards, non-vested restricted stock | $

Note 12 - Stock-based Compens43

Note 12 - Stock-based Compensation - Fair Value of Option Assumptions (Details) - Employee Stock Option [Member] - Minimum [Member]	3 Months Ended
	Mar. 31, 2018
Risk-free interest rate	2.82%
Expected volatility	99.90%
Expected life (Year)	10 years
Expected dividend yield	0.00%

Note 13 - Earn-out Milestone 44

Note 13 - Earn-out Milestone Liability (Details Textual) - USD ($)	1 Months Ended	3 Months Ended		12 Months Ended		15 Months Ended
	Jun. 20, 2014	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017	Dec. 31, 2016	Mar. 31, 2018
Gain (Loss) from Change in Fair Value of Earn out Milestone Liability		$ 270,195
Minimum [Member]
Risk Adjusted Assessment of Each Milestone		35.00%	50.00%	35.00%	50.00%	35.00%
Estimated Time to Achieve the Milestone		1 year 29 days	1 year 273 days	1 year 120 days	2 years
Maximum [Member]
Risk Adjusted Assessment of Each Milestone		80.00%	80.00%	80.00%	80.00%	80.00%
Estimated Time to Achieve the Milestone		1 year 91 days	2 years 91 days	1 year 182 days	2 years 182 days
EGEN Inc [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	$ 30,400,000			$ 24,400,000
Business Combination, Consideration Transferred, Liabilities Incurred	$ 13,900,000	$ 12,800,000	$ 13,500,000	$ 12,500,000	$ 13,200,000
Gain (Loss) from Change in Fair Value of Earn out Milestone Liability			$ 283,751			$ 270,195
EGEN Inc [Member] | Minimum [Member]
Risk Adjusted Assessment of Each Milestone	10.00%
Estimated Time to Achieve the Milestone	1 year 182 days
EGEN Inc [Member] | Maximum [Member]
Risk Adjusted Assessment of Each Milestone	67.00%
Estimated Time to Achieve the Milestone	2 years 182 days

Note 13 - Earn-out Milestone 45

Note 13 - Earn-out Milestone Liability - Summary of the Changes in the Earn-out Milestone Liability (Details)	3 Months Ended
	Mar. 31, 2018USD ($)
Balance	$ 12,538,525
Non-cash charge from the adjustment for the change in fair value included in net loss	270,195
Balance	$ 12,808,720

Note 13 - Earn-out Milestone 46

Note 13 - Earn-out Milestone Liability - Schedule of Milestone Risk-adjustment Assessment (Details)	3 Months Ended		12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017	Dec. 31, 2016
Measurement Input, Discount Rate [Member]
Discount rate	9	9	9	9
Minimum [Member]
Risk-adjustment assessment	35.00%	50.00%	35.00%	50.00%
Estimated time to achieve (Year)	1 year 29 days	1 year 273 days	1 year 120 days	2 years
Maximum [Member]
Risk-adjustment assessment	80.00%	80.00%	80.00%	80.00%
Estimated time to achieve (Year)	1 year 91 days	2 years 91 days	1 year 182 days	2 years 182 days

Note 14 - Contingent Liabilit47

Note 14 - Contingent Liabilities and Commitments (Details Textual)	1 Months Ended
	Jan. 31, 2018USD ($)ft²	Apr. 30, 2017USD ($)ft²	Apr. 30, 2012USD ($)	Jul. 31, 2011ft²	Mar. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Jun. 30, 2014ft²
Contractual Obligation, Total					$ 837,955	$ 665,373
Standby Letters of Credit [Member]
Contractual Obligation Reduction Nineteen Months from Initial Term			$ 50,000
Contractual Obligation Remaining			100,000
Lawrenceville New Jersey [Member]
Area of Real Estate Property | ft²		7,565		10,870			11,500
Lessee, Operating Lease, Term of Contract		5 years 120 days		5 years 180 days
Number of Months in Which Free Rent Is Provided		120 days		180 days
Payments for Rent			23,000
Operating Leases, Monthly Rent Payment in First Year		$ 18,900
Operating Leases, Monthly Rent Payment in Final Year		$ 20,500
Lawrenceville New Jersey [Member] | Standby Letters of Credit [Member]
Contractual Obligation, Total			$ 250,000
Premises Located in Huntsville Alabama [Member]
Area of Real Estate Property | ft²	9,049
Lessee, Operating Lease, Term of Contract	5 years
Operating Leases, Monthly Rent Payment	$ 18,100

Note 15 - Technology Developm48

Note 15 - Technology Development and Licensing Agreements (Details Textual) - USD ($) $ in Millions	Jan. 18, 2013	Mar. 31, 2013
Deferred Revenue		$ 5
Deferred Revenue Amortization Period		10 years
Hisun [Member]
Proceeds from License Fees Received	$ 5